

1 **Detection of *Hepatitis A* (HAV) in wastewater indicates widespread national**
2 **distribution and association with socioeconomic indicators of vulnerability**

3
4 **Alessandro Zulli¹, Elana M. G. Chan¹, Alexandria B. Boehm^{1*}**

5
6 1. Department of Civil and Environmental Engineering, Stanford University, 473 Via Ortega,
7 Stanford, California, 94305

8
9
10 * Corresponding author: aboehm@stanford.edu

11
12 **Abstract**

13 Wastewater-based epidemiology, which seeks to assess disease occurrence in communities
14 through measurements of infectious disease biomarkers in wastewater, may represent a
15 valuable tool for understanding occurrence of hepatitis A infections in communities. In this
16 study, we measured concentrations of *Hepatitis A* (HAV) RNA, in samples from 191
17 wastewater treatment plants spanning 40 US states and the District of Columbia from
18 September 2023 to June 2024 and compared the measurements with traditional measures of
19 disease occurrence. Nationally, 13.76% of the 21,602 wastewater samples were positive for
20 HAV RNA, and both concentrations and positivity rates were associated with NNDSS hepatitis A
21 case data nationally (Kendall rank correlation coefficient = 0.20, concentrations; and 0.33,
22 positivity rate; both $p < 0.05$). We further demonstrated that higher rates of wastewater HAV
23 detection were positively associated with socioeconomic indicators of vulnerability including
24 homelessness and drug overdose deaths (both $p < 0.0001$). Areas with above average levels of
25 homelessness were 48% more likely to have HAV wastewater detections, while areas with
26 above average levels of drug overdose deaths were 14% more likely to have HAV wastewater
27 detections. Using more granular case data, we present a case study in the state of Maine that
28 reinforces these results and suggests a potential lead time for wastewater over clinical case
29 detection and exposure events. The ability to detect HAV RNA in wastewater before clinical
30 cases emerge could allow public health officials to implement targeted interventions like
31 vaccination campaigns.

32
33 **Importance**

34 Despite the existence of a highly effective vaccine for Hepatitis A, outbreaks in vulnerable
35 populations remain common. The disease can be asymptomatic or subclinical, and
36 disproportionately impacts populations with inadequate access to healthcare, leading to a
37 severe underestimation of the occurrence of this viral infection. This study investigates the
38 potential for wastewater measurements of biomarkers of the causative agent of hepatitis A
39 (HAV RNA) to provide insights into disease occurrence. Results highlight the potential for
40 wastewater-based epidemiology to be a complementary tool to traditional surveillance for
41 monitoring and controlling HAV transmission.

42
43

44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87

Introduction

Hepatitis A outbreaks have rapidly become a persistent and severe public health threat in the United States amongst vulnerable populations such as men who have sex with men, persons who use drugs and persons experiencing homelessness.¹⁻³ Hepatitis A is a contagious liver infection caused by the *Hepatovirus A* virus (HAV) and transmitted through person-to-person contact or by ingesting contaminated food and water.^{4,5} Globally, the virus is particularly common in low and middle income countries, with 90% of children in these areas having been infected by age 10.⁶ Annually, HAV is responsible for an estimated 39,000 deaths, 1.4 million symptomatic infections, and 158.9 million total infections worldwide.^{7,8} Despite the virus's worldwide ubiquity, populations in high income countries with high levels of access to clean water and improve sanitation, such as the United States (US), are susceptible to HAV due to a lack of childhood exposure and/or vaccination (74% susceptible).^{5,9} This is of particular concern in recent years as despite the availability of an effective vaccine and well-understood hygiene-based prevention measures, infections have increased in high-income countries, exacerbated by socioeconomic factors and increasing globalization.^{1,5,9-11}

The introduction of the HAV vaccine in 1996 led to a 95% decrease in annual cases in the US by 2011.¹¹ Despite these successful mitigation efforts, cases began to rise again in 2012, and outbreaks began to be recognized nationwide in 2016.¹¹ Between 2016 and the present (2024), 37 states have suffered outbreaks of the virus, resulting in 44,926 cases, 27,457 hospitalizations, and 424 deaths.³ These outbreaks have largely occurred within vulnerable populations of persons reporting drug use and experiencing homelessness, who are often unvaccinated.^{11,12} While hepatitis A has been a nationally notifiable disease since 1966, it is often asymptomatic and affects populations with inadequate access to healthcare, leading to a severe underestimation of the occurrence of this viral infection.^{1,2,10,13} This has lead to increasing interest in alternative methods of monitoring such as wastewater.¹⁴

HAV infection presents clinically with several gastrointestinal symptoms including nausea, vomiting, diarrhea, and dark-coloured urine.^{5,6,11} HAV is mainly transmitted through person-to-person contact or the ingestion of contaminated food or water.^{4,5} Previous studies have shown HAV detection in stool and urine, with concentrations in stool being similar to serum levels of the virus.¹⁵⁻¹⁸ Further, HAV has been shown to be highly prevalent in wastewater, with a recent meta-analysis reporting 31.4% of all wastewater samples positive for the virus.^{14,19,20} A study in Cordoba, Argentina, demonstrated that the percentage of wastewater samples positive for HAV coincided with known outbreaks.¹⁴ These findings, along with known gaps in detection of HAV in vulnerable populations, makes HAV an ideal candidate for the implementation of wastewater monitoring.^{9,11,12}

In this study, we measured concentrations of HAV genomic RNA in samples from 191 wastewater treatment plants spanning 40 U.S. states and the District of Columbia from 11 September 2023 to 1 June 2024 and compared the measurements with traditional measures of

88 disease occurrence. We demonstrate that detections and concentrations of HAV RNA in
89 wastewater are associated with incident HAV cases in the population, compare the frequency of
90 detection of HAV in wastewater to the prevalence of known risk-factors such as drug use and
91 homelessness, and present a detailed case study of a known outbreak in Maine. Together, the
92 findings demonstrate the potential for using wastewater surveillance to inform public health
93 interventions.

94
95
96

97 **Methods**

98
99 This study was reviewed by the Stanford University Ethical Review Board (IRB) and determined
100 that this project does not meet the definition of human subject research as defined in federal
101 regulations 45 CFR 46.102 or 21 CFR 50.3.

102
103 **Wastewater data: sample collection.** Wastewater measurements were made prospectively as
104 part of an ongoing wastewater monitoring program. Between 11 September 2023 and 1 June
105 2024, wastewater samples (either 24-hour composited influent or grab samples from the
106 primary clarifier) were collected by wastewater treatment plant staff. Samples were typically
107 obtained three times per week, but as frequently as daily, and shipped overnight to the
108 laboratory at 4°C and processed immediately upon receipt with no storage. Samples were
109 collected from 191 distinct wastewater treatment plants (WWTPs) across a total of 40 US states
110 and the District of Columbia (Table S1) for a total of 21,471 samples.

111
112 **Wastewater data: pre-analytical processing.** Several studies have demonstrated that viruses,
113 including HAV, partition favorably to the solid fraction of wastewater.^{18,21,22} As a result, HAV
114 nucleic acids were measured in the solid phase of wastewater for this project. Details of the
115 specific wastewater solid isolation protocols and nucleic acid extraction methods are presented
116 in Boehm et al.²³ In short, solids were isolated (dewatered) from samples by centrifugation and
117 then an aliquot was suspended at 75 mg/ml in bovine coronavirus vaccine (BCoV) spiked buffer.
118 After homogenization and additional centrifugation, the 300 µl of supernatant was input into a
119 commercial nucleic acid extraction kit, and then an inhibitor removal kit; the resultant purified
120 nucleic-acid extract was 50 µl. Negative extraction controls consisted of BCoV spiked into
121 buffer. Nucleic acids were extracted from 6 or 10 (Table S1) replicate aliquots of each sample
122 and used immediately as template (no storage) in ddRT-PCR, as described below. The dry
123 weight of the solids were determined using oven drying using an additional aliquot of dewatered
124 solids.²³

125
126 **Wastewater data: analytical processing.** Droplet digital reverse transcription polymerase
127 chain reaction (ddRT-PCR) was used to measure concentrations of nucleic acid targets. The
128 HAV assay is the assay originally published by Jothikumar et al. that targets the 5' untranslated
129 region (UTR) of the HAV RNA genome.²⁴ Those authors thoroughly confirmed the assay
130 sensitivity and specificity for HAV virus. The assay was run in multiplex using a probe-mixing
131 approach. The other assays that were multiplexed included those targeting influenza A and B
132 virus, the N gene of SARS-CoV-2, respiratory syncytial virus, norovirus GII, and rotavirus;
133 results for these assays are not provided herein. Experiments showed that the multiplexed
134 assays do not interfere with each other (see SI and Figure S1). Pepper mild mottle virus
135 (PMMoV) was also measured as an endogenous positive control and BCoV was used as a
136 spiked in control; these assays were run in duplex as described elsewhere.²⁵ Each of the

137 replicate nucleic-acid extracts was run in its own well to measure HAV (6 or 10 wells per
138 sample) and 2 randomly chosen extracts were run in 2 wells to measure PMMoV and BCoV.
139 The exception was the samples for which 10 replicate extracts were available; for these, each of
140 the 10 replicates were run in their own well to measure PMMoV and BCoV (Table S1). Samples
141 were run on 96 well plates, and each plate contained one well consisting of a positive PCR
142 control, two no template controls, and two negative extraction controls. The positive control for
143 HAV was synthetic cDNA (ATCC VR-3257SD), positive controls for PMMoV and BCoV are
144 described elsewhere.²⁵

145
146 Table 1. Primers and probes used for detection of *Hepatitis A Virus* (HAV) nucleic acids, published
147 and validated by Jothikumar et al.²⁴ Primers and probes were purchased from Integrated DNA
148 Technologies (Coralville, IA, USA). The probes contained fluorescent molecule FAM and
149 quenchers (5' FAM/ZEN/3' IBFQ); FAM, fluorescein amidite; ZEN, a proprietary internal
150 quencher from Integrated DNA Technologies (Coralville, IA, USA); and IBFQ, Iowa Black FQ.
151 Amplicon size is 89 base pairs.

152

Forward	GGTAGGCTACGGGTGAAAC
Reverse	AACAACCTACCAATATCCGC
Probe	CTTAGGCTAATACTTCTATGAAGAGATGC

153

154

155 ddRT-PCR was performed on 20 µl samples from a 22 µl reaction volume, prepared using 5.5 µl
156 template, mixed with 5.5 µl of One-Step RT-ddPCR Advanced Kit for Probes (Bio-Rad
157 1863021), 2.2 µl of 200 U/µl Reverse Transcriptase, 1.1 µl of 300 mM dithiothreitol (DTT) and
158 primers and probes mixtures at a final concentration of 900 nM and 250 nM respectively. Primer
159 and probes for assays were purchased from Integrated DNA Technologies (IDT, San Diego,
160 CA) (Table 2). HAV was measured in reactions using undiluted template whereas PMMoV and
161 BCoV were measured using template diluted 1:100 in molecular grade water.

162

163 Droplets were generated using the AutoDG Automated Droplet Generator (Bio-Rad, Hercules,
164 CA). PCR was performed using Mastercycler Pro (Eppendorf, Enfield, CT) with the following
165 cycling conditions: reverse transcription at 50°C for 60 minutes, enzyme activation at 95°C for 5
166 minutes, 40 cycles of denaturation at 95°C for 30 seconds and annealing and extension at 59°C
167 (for HAV) or 56°C (for PMMoV and BCoV) for 30 seconds, enzyme deactivation at 98°C for 10
168 minutes then an indefinite hold at 4°C. The ramp rate for temperature changes were set to
169 2°C/second and the final hold at 4°C was performed for a minimum of 30 minutes to allow the
170 droplets to stabilize. Droplets were analyzed using the QX200 (PMMoV/BCoV) or the QX600
171 Droplet Reader (HAV) (Bio-Rad). A well had to have over 10,000 droplets for inclusion in the
172 analysis. All liquid transfers were performed using the Agilent Bravo (Agilent Technologies,
173 Santa Clara, CA).

174

175 Thresholding was done using QuantaSoft™ Analysis Pro Software (Bio-Rad, version 1.0.596)
176 and QX Manager Software (Bio-Rad, version 2.0). Replicate wells were merged for analysis of
177 each sample. In order for a sample to be recorded as positive, it had to have at least 3 positive
178 droplets.

179

180 Concentrations of RNA targets were converted to concentrations in units of copies (cp)/g dry
181 weight using dimensional analysis.²⁶ The error is reported as standard deviations and includes
182 the errors associated with the Poisson distribution and the variability among the replicate wells.
183 Three positive droplets across merged wells corresponds to a concentration between ~500-
184 1000 cp/g; the range in values is a result of the range in the equivalent mass of dry solids added
185 to the wells and the number of wells (6 or 10). Data collected as part of the study are available
186 from the Stanford Digital Repository (<https://purl.stanford.edu/qf850cv6453>).

187
188 **Clinical surveillance data.** The National Notifiable Disease Surveillance System (NNDSS) is a
189 nationwide collaboration to which health departments share health information about nationally
190 notifiable infectious and noninfectious diseases.²⁷ Total case reports are compiled on a weekly
191 basis using data from 50 states, the District of Columbia, New York City, and 5 territories. For
192 this study, we used publicly available information on NNDSS for laboratory-confirmed HAV
193 incident cases from 1 July, 2023 to 1 June, 2024. Dates of case determination varied but
194 included the following in order of preference: date of disease start, date of diagnosis, date of
195 laboratory result, date of first report to public health system, or date of state report.²⁸ This case
196 data were adjusted for population based on data from the US census and converted to a rate of
197 cases per 100,000 population.²⁹ While this dataset is limited to facilities which report cases to
198 the NNDSS system, it is the most complete dataset available for comparisons across the entire
199 United States.

200
201 For a more focused comparison with potentially more timely and time-resolved data, we
202 conducted an in depth analysis using data from the state of Maine. The state of Maine was
203 identified as of particular interest due to a high occurrence of the HAV nucleic acid targets in
204 wastewater (described in results), a high rate of clinical cases and known outbreaks during the
205 study period.^{1,3,30} Case data for the state of Maine were provided through the Division of
206 Disease Surveillance in the Maine Department of Health Human Services (MDPH), which is
207 available upon request.³¹ The data are provided as the first positive test for each de-identified
208 individual by date of specimen collection. This de-identified data were reported by date of
209 specimen collection.

210
211 **Homelessness and drug overdose data.** Data about individuals experiencing homelessness
212 was aggregated from the US Department of Housing and Urban Development and the 2023
213 Annual Homeless Assessment Report to Congress.^{32,33} Rates are reported as unhoused
214 persons per 10,000 population at the state level. Drug overdose data were aggregated from the
215 CDC WONDER database and reported as the number of deaths per 100,000 population at the
216 state level.^{34,35} Data on individuals experiencing homelessness and drug overdoses was
217 available as yearly averages on a state level basis for 2023 at the latest and is assumed to be
218 representative of values during our study period (2023-2024).

219
220 **Data analysis.** We ran several comparisons between summary statistics of HAV concentrations
221 in wastewater and clinical surveillance case rates (cases per 100,000/week). Case data from
222 NNDSS, available on a weekly basis, was used by converting cases to cases per 100,000
223 people for each state. First, we ran comparisons between weekly wastewater concentrations
224 and weekly clinical cases aggregated at the national and state level. Non-detect results in
225 wastewater were treated as 0 copies per gram dry weight (cp/g). Weekly wastewater
226 concentrations were calculated by taking the Morbidity and Mortality Weekly Report (MMWR)
227 weekly average concentrations at each WWTP and adjusting their contributions to the state total
228 as previously described by population (SI Eq 1).³⁶ We then calculated the weekly percentage of
229 positive detections of wastewater HAV by counting all positive observations for a single WWTP
230 and dividing by the total number of observations in each week. This process was repeated by

231 aggregating data on a state basis. All weekly data were aggregated by MMWR week. Kendall's
232 tau rank correlation coefficients were used to assess the association between weekly NNDSS
233 case rates and both average wastewater concentrations and percentage positive detections at
234 both the state and national levels.

235
236 We also assessed the relationship between the percentage of positive wastewater detections of
237 HAV and indicators of homelessness and drug overdose deaths.¹⁴ Percentage of positive
238 wastewater detections was used in accordance with previous studies.¹⁴ For this analysis, the
239 percent of positive wastewater detections over the entire study period was calculated for each
240 state. We then separated the states into two groups; one group with above or equal to the mean
241 and one group with below mean metrics of individuals experiencing homelessness, and also
242 drug overdose deaths. We then calculated the mean percentage of positive wastewater
243 detections in each group across the study period. Statistical significance and 95% confidence
244 intervals were calculated through bootstrapping.³⁷ The null hypothesis tested was that there was
245 no significant difference between the percentage of wastewater detections in the two groups of
246 observations. For each variable and group, a distribution of values was generated through
247 random sampling with replacement 30,000 times.

248
249 We further present an in-depth case study comparing wastewater HAV nucleic acid
250 concentrations and new HAV diagnoses in the state of Maine. In addition to the analyses
251 described above, we calculated Kendall's tau rank correlation coefficient between monthly
252 average concentrations and monthly diagnoses, and present cross-correlation data to examine
253 whether wastewater HAV data lead or lag diagnoses. We focused on two specific counties with
254 identified hepatitis A outbreaks for which the communities were served by WWTPs participating
255 in the study: Androscoggin and Cumberland. Case data were used in conjunction to identify
256 these counties as having a high likelihood of HAV transmission. Kendall's rank correlation
257 coefficient was used for cross-correlation analysis on a weekly basis.

258
259 All statistical analyses were performed in RStudio using R Statistical Software (version 4.3.2).³⁸
260 The p-value threshold to assign significance was 0.05. Monthly average concentrations were
261 calculated using simple averages, and cross-correlation was assessed using Kendall's rank
262 correlation coefficient and the ccf() function from the t-series package (version 0.10-56).

263

264 **Results**

265

266 **QA/QC.** Results are reported following the Environmental Microbiology Minimal Information
267 (EMMI) guidelines (Figure S2). All positive and negative controls were positive and negative,
268 respectively. Median (IQR) BCoV recoveries across all wastewater samples were 1.07 (0.81,
269 1.42) indicating good recovery across all samples. Recoveries exceeding 1 are the result of
270 uncertainties in the measurement of BCoV added to the buffer matrix. PMMoV levels were
271 elevated in all samples indicating lack of gross extraction failures (median = 4.6×10^8 cp/g, min =
272 5.0×10^5 cp/g, max = 2.02×10^{11} cp/g, IQR = 1.8×10^8 - 6.2×10^8).

273


274 **National overview.** The study period ran from 11 September 2023 to 1 June 2024 and spanned
275 191 distinct WWTPs in 40 states and the District of Columbia (Table S1). States had between 1
276 and 57 treatment plants enrolled. Population coverage of the sewersheds as a function of total
277 state population ranged from 0.13% to 59.5% of the population of each state (median: 5.75%).
278 Each WWTP provided between 31 to 275 samples during the study period (median=113). In
279 total, 21,602 samples were collected and analyzed across all WWTPs. HAV RNA
280 concentrations ranged from below the limit of detection (approximately 1000 cp/g) to

281 ~12,000,000 cp/g, with 13.8% of all samples having detectable HAV RNA. Of the 40 states
282 included in the study, 38 of them and the District of Columbia had at least one positive HAV
283 detection (Mississippi and Washington state had no positive detections), and of the 191
284 WWTPs, 147 had at least one positive HAV detection (77%). The percentage of positive
285 samples in WWTPs with at least one detection ranged between 0.9% to 95.1%. Table S2
286 provides a summary of percentage positive detections at each WWTP. Detections of HAV RNA
287 varied widely by location. The highest percentage of detections was found in Portland Water
288 District in Maine (93.47%), while the lowest levels of detection were 0% in 43 WWTPs. At the
289 state level, the highest levels of detection were found in Massachusetts, Kansas, and Maine
290 (45.1%, 37.9%, 34.27%) while the lowest levels of detection were in Washington and
291 Mississippi (0%). Nationally, 13.76% of all samples were positive for HAV RNA.

292
293 Case rates from the NNDSS were compared to population weighted wastewater concentrations
294 on a statewide basis. Table 1 shows Kendall's tau for each state. Five (of 40) states had
295 positive and significant correlations ($p < 0.05$). States marked with NA (7 states total) had either
296 no detectable HAV in wastewater or 0 recorded HAV cases, leading to no rank-correlation
297 coefficient being calculated. For the remaining 28 states, the rank correlation was not
298 statistically different from 0.

299
300 We calculated correlations on a national level between weekly population weighted average
301 wastewater concentrations and weekly new cases as reported by NNDSS (Kendall's $\tau = 0.20$,
302 $p = 0.04963$). We ran the same analysis using the percentage of positive wastewater detections
303 (Kendall's $\tau = 0.33$, $p = 0.001429$). Lastly, we measured the percentage of positive wastewater
304 samples across the entire study for each state and compared these to the total number of cases
305 per 100,000 people in each state during the study period (Kendall's $\tau = 0.38$, $p = 0.006683$). The
306 results are summarized in Figure 2.

307
308



309

310 **Figure 1:** Heatmaps representing nationwide measurements used herein by state. Figure 1a
 311 represents the number of cases per million population as reported by NNDSS. Figure 1b
 312 represents the percentage of wastewater samples positive for HAV aggregated by state. Figure
 313 1c shows the rates of homelessness across states normalized per 10,000 population, and figure
 314 1d represents deaths attributed to drug overdoses in the CDC WONDER database normalized
 315 per 100,000 population.


316
 317 **Table 1:** Table summarizing Kendall's rank correlation, tau, between weekly cases recorded by
 318 NNDSS and weekly average wastewater concentrations. NA indicates that either the
 319 concentration values or case values were all 0 for a state, which meant no Kendall's rank
 320 correlation coefficient could be calculated, n represents the number of observations in each
 321 group (state) and an asterisk next to the state abbreviation indicates that the correlation had a
 322 p-value less than 0.05. DC is Washington DC.

State	tau	P value	n
AK	NA	NA	7
AL*	0.230	0.024	34
AR	-0.063	0.738	34
CA	0.184	0.777	41
CO	0.194	0.612	28
CT	NA	NA	24


DC	-0.015	0.605	20
DE	-0.067	0.729	32
FL	0.135	0.305	36
GA	0.297	0.819	25
HI	NA	NA	17
IA	-0.081	0.796	23
ID	-0.065	0.841	28
IL	0.200	0.906	31
IN	-0.089	0.554	30
KS	-0.024	0.442	36
KY*	0.265	0.006	31
LA	NA	NA	5
MA	0.191	0.232	34
MD*	0.319	0.010	34
ME*	0.407	0.003	32
MI	-0.151	0.143	29
MN	0.151	0.156	28
MS	NA	NA	16
NC	0.342	0.104	32
NE	NA	NA	29
NH	NA	NA	24
NJ	-0.106	0.400	27
NV	0.133	0.914	24
NY	0.268	0.165	26
OH	-0.052	0.472	34
PA	0.241	0.116	36
SD	-0.063	0.812	17

TN	0.181	0.751	31
TX*	0.327	0.039	31
UT	NA	NA	19
VA	-0.239	0.757	34
VT	NA	NA	17
WA	NA	NA	25
WI	-0.042	0.575	31
WV	-0.133	0.530	24


a.



b.




c.



323
 324 **Figure 2:** Summary of national concentrations and percent positive detections of HAV in
 325 wastewater compared to case counts nationally and cases per 100,000 for states. Figure 2a
 326 shows national, population weighted weekly HAV concentrations compared to weekly case
 327 counts as reported to NNDSS. Figure 2b compares the percentage of samples positive for HAV
 328 across all samples to case counts. Figure 2c plots a summary of detection in each state,
 329 comparing the percentage of all samples positive for HAV in the state to cases adjusted by
 330 population.


331
332 **Risk factors.** We aggregated quantitative data on two common risk factors for HAV,
333 homelessness and drug overdose deaths, to determine whether these were associated with
334 HAV detection in wastewater. The yearly average rate of drug overdose deaths across the
335 United States is 32.6 per 100,000 population. We then split our observations at the state level
336 based on this, grouping all observations in areas with equal to or above average rates of drug
337 overdoses together. This resulted in 4,169 observations in the equal to or above average
338 overdose group and 14,836 observations in the below average overdose group. The average
339 percentage of positive wastewater detections in the equal to or above average overdose group
340 was 16.47% (95% CI: 15.35 - 17.60) compared to 14.4% (95% CI: 13.85 - 14.97) in the below
341 average overdose group. These values were significantly different, with a p-value less than
342 0.0001. The average rate of homelessness in the US is 18 per 10,000 population. We split our
343 data in the same way, resulting in 10,261 observations in the equal to or above average
344 homelessness group and 11,286 in the below average homelessness group. The average
345 percentage of positive detections of HAV in the equal to or above average homelessness group
346 was 17.00% (95% CI: 16.28 - 17.74) while it was 11.49% (95% CI: 10.92 - 12.07) in the below
347 average homelessness group. These values were significantly different, with a p-value less than
348 0.0001. These differences represent a 48% higher chance of HAV detection in wastewater in
349 areas with high rates of homelessness and a 14% higher chance of HAV detection in areas with
350 high rates of drug overdoses. Figure 3 summarizes these results.
351




352
353 **Figure 3:** Association between risk factors on wastewater detections of HAV nucleic acids.
354 **Figure 3a** demonstrates significantly higher wastewater detections in states with higher rates of
355 overdose deaths. **Figure 3b** shows the association of homelessness on wastewater detections
356 of HAV, with significantly higher positive rates in states with equal to or above median rates of
357 unhoused individuals. Error bars represent 95% confidence intervals. Null distribution graphs
358 are provided in the SI, Figure S3.
359

360 **Case study: Portland, Maine.**

361 Case data available through NNDSS can be limited, so we identified an area of high HAV
362 occurrence, the state of Maine, and requested county level, daily case data from the Division of
363 Disease Surveillance in the Maine Department of Health Human Services (MDPH). We
364 performed detailed analytical comparisons as a case study. In September of 2023, HAV cases
365 rose in the city of Portland in Cumberland County. In the 8 months between 1 January 2023 to
366 30 August 2023, a total of 3 cases were recorded. Then, in September 2023, 5 cases were
367 identified (Figure 4). An outbreak was declared by the MDPH in October, 2023. Several
368 exposure events were identified by MDPH, all in Cumberland County or the adjacent
369 Androscoggin County. Three WWTP participating in our study are located in these counties,
370 with two in Cumberland and one in Androscoggin (Portland Water District (East End
371 Wastewater Treatment Facility), Brunswick Sewer District and Lewiston Auburn Water Pollution
372 Control Authority). As shown in Figure 4, cases in the counties had a high degree of correlation
373 to wastewater concentrations of HAV averaged on a monthly basis at WWTPs serving the
374 counties. Specifically, we found a Kendall rank correlation coefficient of 0.93 and 0.97 when
375 comparing average monthly wastewater HAV RNA concentrations in each county to monthly
376 cases for Androscoggin and Cumberland county, respectively ($p < 0.001$). Using weekly
377 concentrations and weekly case numbers for these 2 counties, Kendall rank correlation
378 coefficients were 0.53 (Androscoggin, $p < 0.001$) and 0.42 (Cumberland, $p < 0.001$). In
379 Cumberland county, where wastewater monitoring began the outbreak, cross-correlation
380 analysis demonstrated that wastewater data lead clinical surveillance data by a week (Figure 5).
381
382



383
384 **Figure 4:** Figure demonstrating association between HAV wastewater concentrations and
385 cases in Maine. The figures show monthly mean concentrations as a black line, and monthly
386 cases as grey bars. Kendall's tau is provided in the top right. Figure 4a shows these results for
387 Androscoggin county, while figure 4b shows these results for Cumberland county.
388



389
390 **Figure 5:** Raw wastewater concentrations compared to weekly cases, and the accompanying
391 cross-correlation analysis. Concentrations are presented on a log₁₀ scaled y-axis. Figures 5a
392 and 5b are the results for Androscoggin county. Figures 5c and 5d show these results for
393 Cumberland county.

394 **Discussion**

395
396 Previous studies of HAV in wastewater have shown that detection of the virus in wastewater
397 streams is feasible but have largely focused on analyses of the occupational exposure risk that
398 these viruses represent.^{39–42} More recent studies, spurred on by the success of SARS-CoV-2
399 wastewater monitoring and recent HAV outbreaks in the United States, have begun studying the
400 relationship between wastewater concentrations of HAV and laboratory-confirmed clinical
401 cases.^{14,20,43,44} These have shown limited but promising results regarding the forecasting ability
402 of measuring HAV in wastewater.^{14,43} These studies were limited to small spatial scales such as
403 within a single city.^{14,43,45} We present the results of a nationwide wastewater monitoring program
404 covering 40 states and the District of Columbia and demonstrate that HAV RNA wastewater
405 concentrations are associated with disease occurrence in the population at the national level,
406 within some states, and at the county level in Maine. This is despite the fact that the incident
407 case data may be biased to cases of severe disease and may not include undiagnosed and
408 subclinical cases. Further, we show that wastewater detection of HAV RNA is associated with
409 socio-economic indicators of vulnerability that highlight the ability of wastewater monitoring to
410 serve vulnerable populations, and open up the idea of using wastewater monitoring to track the
411 effects of interventions in these populations. Lastly, the detailed case study of HAV outbreaks in
412 Maine demonstrates a potential lead time of wastewater over public health surveillance data in
413 one of two sites.

414
415 There were states for which HAV in wastewater solids was not significantly associated with case
416 rates. Wastewater and case data capture different populations of individuals. Whereas
417 wastewater captures contributions from all infected individuals, including those who may be

418 asymptomatic, case rates only reflect severe cases that are diagnosed and reported to NNDSS;
419 case reporting fidelity and frequency may vary by state. These differences undoubtedly affect
420 the association between wastewater and case rates seen in many of the states.

421
422 Nationally, 13.76% of all wastewater samples were positive for HAV during the study. These
423 results are in agreement with previous studies regarding the presence of HAV in wastewater but
424 those other studies measured HAV in the liquid rather than solid fraction of wastewater. Fantilli
425 et al. measured HAV concentrations in wastewater influent at a treatment plant in Cordoba,
426 Argentina and found similar levels of variability in percentage of detections across locations and
427 time periods (2.9% - 56.5%).¹⁴ They also found that HAV genotypes detected in wastewater
428 samples matched those identified in clinical samples, further confirming that HAV in wastewater
429 can reflect clinical infections. A similar study by Hellmer et al. suggested that due to high levels
430 of shedding of the virus by infected patients, even a single infection could cause large spikes in
431 wastewater concentrations followed by non-detectable concentrations.⁴⁵ This is corroborated by
432 our case study in Maine, where even one detected case in a month appears to reflect higher
433 HAV concentrations. Though limited data is available on HAV in wastewater solids, Yin et al.
434 identified one study that indicated HAV partitioning to solids.⁴⁶

435
436 There are limited data on shedding of HAV in excretions of infected individuals, however, it has
437 been documented in feces, sputum, and urine of infected individuals.^{15-17,47} HAV can be
438 detected in stool up to 45 days after infection, though the concentration of these detections
439 drops off rapidly the week after infection.^{47,48} It has been noted that in some
440 immunocompromised patients, replication of the HAV virus can occur despite vaccination.⁴⁹
441 Hundekar et al. showed that infected asymptomatic persons may shed the virus at elevated
442 concentrations for longer periods of time than symptomatic persons, even if HAV antibodies are
443 present.⁴⁷ Further studies on shedding in unvaccinated and vaccinated individuals, in various
444 bodily excretions, is necessary to further link HAV wastewater concentrations to occurrence of
445 infections in the contributing population.⁴⁹

446
447 The early detection of viral occurrence in a community is a key measure that allows public
448 health officials to enact appropriate responses such as vaccination campaigns. Despite the
449 availability of a vaccine and increasing water, sanitation, hygiene standards, HAV remains one
450 of the most common enteric viruses in the world and is responsible for an estimated 39,000
451 deaths worldwide.^{7,8} Further, increasing levels of hygiene and immunity gaps in adult
452 populations in countries such as the United States have the potential to increase the intensity of
453 outbreaks.^{3,5,12,13,50} Wastewater monitoring represents a rapid method for the detection of
454 infections of HAV, and the results presented in this study support the conclusion that detection
455 in wastewater can be representative of underlying infections and case rates. Therefore,
456 wastewater HAV detections may be useful for health professionals for making informed
457 decisions about where to target limited resources, such as vaccination clinics. The congruence
458 between wastewater and surveillance data, despite the latter's limited availability and resolution,
459 highlights an advantage of using wastewater monitoring for illnesses with limited clinical testing.

460
461

462 Hepatitis A is a disease closely associated with socioeconomic indicators of vulnerability.^{1,12}
463 Worldwide, it is largely driven by lacking sanitary conditions and access to clean water.^{5,8} In the
464 US, it is associated with two major risk factors: homelessness and drug use.^{1,2,10} To identify
465 whether wastewater trends reflected this, drug overdose data and rates of homelessness were
466 compiled for comparison. We then demonstrated that wastewater concentrations reflect this
467 epidemiological trend, with significantly higher concentrations of wastewater HAV in states with
468 higher drug overdose deaths and rates of individuals experiencing homelessness. In areas with
469 high levels of homelessness, we were 48% more likely to detect HAV, while in areas with high
470 rates of drug overdoses, we were 14% more likely to detect HAV. These results show that
471 wastewater concentrations may reflect the underlying presence of HAV in a population, and that
472 wastewater results can help identify at-risk populations, healthcare inequities, and risk factors
473 that public health surveillance case data may miss.

474
475 To corroborate these findings, we present an in-depth analysis of wastewater concentrations
476 and public health surveillance case data in the state of Maine during our monitoring period.
477 Public health surveillance case data were provided at the county level by the Maine Department
478 of Health Human Services. The results of this analysis demonstrate a high degree of agreement
479 between signals (rank correlation coefficient of 0.93 and 0.97 in affected counties), but more
480 importantly, identify a 1 week lead time of wastewater concentrations over public health
481 surveillance case data, and identify sharp increases in concentrations the week before exposure
482 events in Cumberland county. Identifying these spikes in wastewater prior to potential exposure
483 events would allow local health officials to deploy the appropriate resources to track a point
484 source.

485
486 Overall, we demonstrated that wastewater concentrations and percent positive detections of
487 HAV RNA are significantly correlated with NNDSS cases nationally, in some states, and at the
488 county level in Maine, are significantly associated with socioeconomic indicators of vulnerability,
489 and may provide up to a week lead time over transmission events and cases. This opens up the
490 possibility of using HAV wastewater monitoring to enact timely interventions that prevent further
491 spread of illness, such as vaccination clinics or non-pharmaceutical interventions. These
492 interventions are key in the prevention of future outbreaks such as the 2016 HAV outbreak in
493 the US, and can further be used in low- and middle-income regions to identify and target the
494 most at-risk populations for preventative measures.^{3,12} In these regions where HAV is endemic,
495 it will also provide a way of measuring the impact of interventions such as hygiene awareness
496 campaigns in areas with little to no clinical testing.

497
498 The work presented in this study is subject to some limitations. Public health surveillance data
499 were limited to reported HAV cases and were likely not inclusive of all incident cases. Both the
500 wastewater sampling and public health surveillance data are not uniform across the US or
501 individual states, which could have introduced biases into our analyses. Case data is biased
502 towards severe cases where individuals seek care, which underestimates disease prevalence
503 for illnesses such as HAV, where up to 70% of cases are asymptomatic.^{11,13} By comparison,
504 wastewater captures the entire population contributing within the sewershed even those with
505 mild and asymptomatic cases, which is a separate and complementary measurement to public

506 health surveillance cases. Such differences between clinical surveillance and wastewater
507 monitoring data suggest that the two metrics might not be directly comparable, although they
508 are complementary. Within the socioeconomic data available, we were limited to data provided
509 at the state level versus the sewershed level, and homelessness and rates of drug overdoses
510 vary considerably within a state. The exact magnitude of impact of these socioeconomic factors
511 will require further investigation at smaller geographical scales.

512
513 **Acknowledgments.** We thank the participating wastewater treatment plants for their samples
514 for the project.

515 516 **References**

- 517
- 518 (1) Foster, M.; Ramachandran, S.; Myatt, K.; Donovan, D.; Bohm, S.; Fiedler, J.; Barbeau, B.;
519 Collins, J.; Thoroughman, D.; McDonald, E.; Ballard, J.; Eason, J.; Jorgensen, C. Hepatitis
520 A Virus Outbreaks Associated with Drug Use and Homelessness — California, Kentucky,
521 Michigan, and Utah, 2017. *Morb. Mortal. Wkly. Rep.* **2018**, *67* (43), 1208–1210.
 - 522 (2) *Hepatitis infection among people who use or Inject drugs* | CDC.
523 <https://www.cdc.gov/hepatitis/populations/idu.htm> (accessed 2024-03-22).
 - 524 (3) *Hepatitis A Outbreaks in the United States* | CDC.
525 <https://www.cdc.gov/hepatitis/outbreaks/hepatitisaoutbreaks.htm> (accessed 2024-04-01).
 - 526 (4) Hofmeister, M. G.; Xing, J.; Foster, M. A.; Augustine, R. J.; Burkholder, C.; Collins, J.;
527 McBee, S.; Thomasson, E. D.; Thoroughman, D.; Weng, M. K.; Spradling, P. R. Hepatitis A
528 Person-to-Person Outbreaks: Epidemiology, Morbidity Burden, and Factors Associated
529 With Hospitalization—Multiple States, 2016–2019. *J. Infect. Dis.* **2021**, *223* (3), 426–434.
530 <https://doi.org/10.1093/infdis/jiaa636>.
 - 531 (5) Miguères, M.; Lhomme, S.; Izopet, J. Hepatitis A: Epidemiology, High-Risk Groups,
532 Prevention and Research on Antiviral Treatment. *Viruses* **2021**, *13* (10), 1900.
533 <https://doi.org/10.3390/v13101900>.
 - 534 (6) *Hepatitis A*. <https://www.who.int/news-room/fact-sheets/detail/hepatitis-a> (accessed 2024-
535 04-01).
 - 536 (7) Global, Regional, and National Incidence, Prevalence, and Years Lived with Disability for
537 310 Diseases and Injuries, 1990–2015: A Systematic Analysis for the Global Burden of
538 Disease Study 2015. *Lancet Lond. Engl.* **2016**, *388* (10053), 1545–1602.
539 [https://doi.org/10.1016/S0140-6736\(16\)31678-6](https://doi.org/10.1016/S0140-6736(16)31678-6).
 - 540 (8) Cao, G.; Jing, W.; Liu, J.; Liu, M. The Global Trends and Regional Differences in Incidence
541 and Mortality of Hepatitis A from 1990 to 2019 and Implications for Its Prevention. *Hepatol.*
542 *Int.* **2021**, *15* (5), 1068–1082. <https://doi.org/10.1007/s12072-021-10232-4>.
 - 543 (9) Yin, S.; Barker, L.; Ly, K. N.; Kilmer, G.; Foster, M. A.; Drobeniuc, J.; Jiles, R. B.
544 Susceptibility to Hepatitis A Virus Infection in the United States, 2007–2016. *Clin. Infect.*
545 *Dis.* **2020**, *71* (10), e571–e579. <https://doi.org/10.1093/cid/ciaa298>.
 - 546 (10) Peak, C. M.; Stous, S. S.; Healy, J. M.; Hofmeister, M. G.; Lin, Y.; Ramachandran, S.;
547 Foster, M. A.; Kao, A.; McDonald, E. C. Homelessness and Hepatitis A—San Diego
548 County, 2016–2018. *Clin. Infect. Dis.* **2020**, *71* (1), 14–21.
549 <https://doi.org/10.1093/cid/ciz788>.
 - 550 (11) *Pinkbook: Hepatitis A* | CDC. <https://www.cdc.gov/vaccines/pubs/pinkbook/hepa.html>
551 (accessed 2024-04-01).
 - 552 (12) Partida, D.; Powell, J.; Gonzalez, D.; Khalili, M. Gaps in Hepatitis A and Hepatitis B
553 Vaccination Among Hepatitis C Antibody–Positive Individuals Experiencing Homelessness.
554 *Open Forum Infect. Dis.* **2022**, *9* (5), ofac175. <https://doi.org/10.1093/ofid/ofac175>.

- 555 (13) Savage, R. D.; Rosella, L. C.; Brown, K. A.; Khan, K.; Crowcroft, N. S. Underreporting of
556 Hepatitis A in Non-Endemic Countries: A Systematic Review and Meta-Analysis. *BMC*
557 *Infect. Dis.* **2016**, *16*, 281. <https://doi.org/10.1186/s12879-016-1636-6>.
- 558 (14) Fantilli, A.; Cola, G. D.; Castro, G.; Sicilia, P.; Cachi, A. M.; de los Angeles Marinzalda, M.;
559 Ibarra, G.; López, L.; Valduvino, C.; Barbás, G.; Nates, S.; Masachessi, G.; Pisano, M. B.;
560 Ré, V. Hepatitis A Virus Monitoring in Wastewater: A Complementary Tool to Clinical
561 Surveillance. *Water Res.* **2023**, *241*, 120102. <https://doi.org/10.1016/j.watres.2023.120102>.
- 562 (15) Joshi, M. S.; Bhalla, S.; Kalrao, V. R.; Dhongade, R. K.; Chitambar, S. D. Exploring the
563 Concurrent Presence of Hepatitis A Virus Genome in Serum, Stool, Saliva, and Urine
564 Samples of Hepatitis A Patients. *Diagn. Microbiol. Infect. Dis.* **2014**, *78* (4), 379–382.
565 <https://doi.org/10.1016/j.diagmicrobio.2013.12.013>.
- 566 (16) Yotsuyanagi, H.; Koike, K.; Yasuda, K.; Moriya, K.; Shintani, Y.; Fujie, H.; Kurokawa, K.;
567 Iino, S. Prolonged Fecal Excretion of Hepatitis A Virus in Adult Patients with Hepatitis A as
568 Determined by Polymerase Chain Reaction. *Hepatology* **1996**, *24* (1), 10–13.
569 <https://doi.org/10.1002/hep.510240103>.
- 570 (17) Kozak, R. A.; Rutherford, C.; Richard-Greenblatt, M.; Chau, N. Y. E.; Cabrera, A.; Biondi,
571 M.; Borlang, J.; Day, J.; Osiowy, C.; Ramachandran, S.; Mayer, N.; Glaser, L.; Smieja, M.
572 Development and Evaluation of a Molecular Hepatitis A Virus Assay for Serum and Stool
573 Specimens. *Viruses* **2022**, *14* (1), 159. <https://doi.org/10.3390/v14010159>.
- 574 (18) Roldan-Hernandez, L.; Oost, C. V.; Boehm, A. Solid–Liquid Partitioning of Dengue,
575 West Nile, Zika, Hepatitis A, Influenza A, and SARS-CoV-2 Viruses in Wastewater from
576 across the USA. *Environ. Sci. Water Res. Technol.* **2024**.
577 <https://doi.org/10.1039/D4EW00225C>.
- 578 (19) Takuissu, G. R.; Kenmoe, S.; Ebogo-Belobo, J. T.; Kengne-Ndé, C.; Mbagha, D. S.; Bowo-
579 Ngandji, A.; Ndzie Ondigui, J. L.; Kenfack-Momo, R.; Tchatchouang, S.; Kenfack-Zanguim,
580 J.; Lontuo Fogang, R.; Zeuko'o Menkem, E.; Kame-Ngasse, G. I.; Magoudjou-Pekam, J.
581 N.; Veneri, C.; Mancini, P.; Bonanno Ferraro, G.; Iaconelli, M.; Orlandi, L.; Del Giudice, C.;
582 Suffredini, E.; La Rosa, G. Occurrence of Hepatitis A Virus in Water Matrices: A
583 Systematic Review and Meta-Analysis. *Int. J. Environ. Res. Public Health* **2023**, *20* (2),
584 1054. <https://doi.org/10.3390/ijerph20021054>.
- 585 (20) La Rosa, G.; Libera, S. D.; Iaconelli, M.; Ciccaglione, A. R.; Bruni, R.; Taffon, S.; Equestre,
586 M.; Alfonsi, V.; Rizzo, C.; Tosti, M. E.; Chironna, M.; Romanò, L.; Zanetti, A. R.; Muscillo,
587 M. Surveillance of Hepatitis A Virus in Urban Sewages and Comparison with Cases
588 Notified in the Course of an Outbreak, Italy 2013. *BMC Infect. Dis.* **2014**, *14*, 419.
589 <https://doi.org/10.1186/1471-2334-14-419>.
- 590 (21) Roldan-Hernandez, L.; Graham, K. E.; Duong, D.; Boehm, A. B. Persistence of
591 Endogenous SARS-CoV-2 and Pepper Mild Mottle Virus RNA in Wastewater-Settled
592 Solids. *ACS EST Water* **2022**, *2* (11), 1944–1952.
593 <https://doi.org/10.1021/acsestwater.2c00003>.
- 594 (22) Roldan-Hernandez, L.; Boehm, A. B. Adsorption of Respiratory Syncytial Virus, Rhinovirus,
595 SARS-CoV-2, and F+ Bacteriophage MS2 RNA onto Wastewater Solids from Raw
596 Wastewater. *Environ. Sci. Technol.* **2023**, *57* (36), 13346–13355.
597 <https://doi.org/10.1021/acs.est.3c03376>.
- 598 (23) Boehm, A. B.; Wolfe, M. K.; Wigginton, K. R.; Bidwell, A.; White, B. J.; Hughes, B.; Duong,
599 D.; Chan-Herur, V.; Bischel, H. N.; Naughton, C. C. Human Viral Nucleic Acids
600 Concentrations in Wastewater Solids from Central and Coastal California USA. *Sci. Data*
601 **2023**, *10* (1), 396. <https://doi.org/10.1038/s41597-023-02297-7>.
- 602 (24) Jothikumar, N.; Cromeans, T. L.; Sobsey, M. D.; Robertson, B. H. Development and
603 Evaluation of a Broadly Reactive TaqMan Assay for Rapid Detection of Hepatitis A Virus.
604 *Appl. Environ. Microbiol.* **2005**, *71* (6), 3359–3363. [https://doi.org/10.1128/AEM.71.6.3359-](https://doi.org/10.1128/AEM.71.6.3359-3363.2005)
605 [3363.2005](https://doi.org/10.1128/AEM.71.6.3359-3363.2005).

- 606 (25) Boehm, A.; Wolfe, M.; Wigginton, K.; Bidwell, A.; White, B.; Duong, D.; Hughes, B.; Chan-
607 Herur, V.; Naughton, C.; Bischel, H. Human Viral Nucleic Acids Concentrations in
608 Wastewater Solids from Central and Coastal California, USA. *Boehm Research Group at*
609 *Stanford*, 2023. <https://doi.org/10.25740/cx529np1130>.
- 610 (26) Topol, A.; Wolfe, M.; Wigginton, K.; White, B.; Boehm, A. High Throughput RNA Extraction
611 and PCR Inhibitor Removal of Settled Solids for Wastewater Surveillance of S... **2021**.
- 612 (27) *National Notifiable Diseases Surveillance System (NNDSS) - Healthy People 2030* |
613 *health.gov*. [https://health.gov/healthypeople/objectives-and-data/data-sources-and-](https://health.gov/healthypeople/objectives-and-data/data-sources-and-methods/data-sources/national-notifiable-diseases-surveillance-system-nndss)
614 [methods/data-sources/national-notifiable-diseases-surveillance-system-nndss](https://health.gov/healthypeople/objectives-and-data/data-sources-and-methods/data-sources/national-notifiable-diseases-surveillance-system-nndss) (accessed
615 2024-01-26).
- 616 (28) Weston, E. (CDC/OID/NCIRD). *Guidance on classifying STD case reports into MMWR*
617 *week*. <https://www.cdc.gov/std/program/mmwr-week-guidance-cleared-feb-2021.pdf>.
- 618 (29) Bureau, U. C. *Population Data*. Census.gov.
619 <https://www.census.gov/topics/population/data.html> (accessed 2024-06-29).
- 620 (30) *News | Department of Health and Human Services*. Maine DHHS.
621 <http://www.maine.gov/dhhs/news> (accessed 2024-06-29).
- 622 (31) *Data Request Form HIV, STD and Viral Hepatitis Program - Division of Disease*
623 *Surveillance - MeCDC; DHHS Maine*. [https://www.maine.gov/dhhs/mecdc/infectious-](https://www.maine.gov/dhhs/mecdc/infectious-disease/hiv-std/data-request.shtml)
624 [disease/hiv-std/data-request.shtml](https://www.maine.gov/dhhs/mecdc/infectious-disease/hiv-std/data-request.shtml) (accessed 2024-06-02).
- 625 (32) *DATASETS | HUD USER*. https://www.huduser.gov/portal/pdrdatas_landing.html
626 (accessed 2024-06-03).
- 627 (33) The 2022 Annual Homelessness Assessment Report (AHAR to Congress) Part 1: Point-In-
628 Time Estimates of Homelessness, December 2022.
- 629 (34) *Drug Overdose Mortality by State*.
630 [https://www.cdc.gov/nchs/pressroom/sosmap/drug_poisoning_mortality/drug_poisoning.ht](https://www.cdc.gov/nchs/pressroom/sosmap/drug_poisoning_mortality/drug_poisoning.htm)
631 [m](https://www.cdc.gov/nchs/pressroom/sosmap/drug_poisoning_mortality/drug_poisoning.htm) (accessed 2024-06-03).
- 632 (35) *CDC WONDER*. <https://wonder.cdc.gov/> (accessed 2024-06-03).
- 633 (36) Zulli, A.; Varkila, M. R. J.; Parsonnet, J.; Wolfe, M. K.; Boehm, A. B. Observations of
634 Respiratory Syncytial Virus (RSV) Nucleic Acids in Wastewater Solids Across the United
635 States in the 2022–2023 Season: Relationships with RSV Infection Positivity and
636 Hospitalization Rates. *ACS EST Water* **2024**. <https://doi.org/10.1021/acsestwater.3c00725>.
- 637 (37) Efron, B. Bootstrap Methods: Another Look at the Jackknife. *Ann. Stat.* **1979**, 7 (1), 1–26.
638 <https://doi.org/10.1214/aos/1176344552>.
- 639 (38) R Core Team (2023). *_R: A Language and Environment for Statistical Computing_*.
640 <https://www.R-project.org/>.
- 641 (39) Espigares, M.; García, F.; Fernández-Crehuet, M.; Álvarez, A.; Gálvez, R. Detection of
642 Hepatitis A Virus in Wastewater. *Environ. Toxicol.* **1999**, 14 (4), 391–396.
643 [https://doi.org/10.1002/\(SICI\)1522-7278\(1999\)14:4<391::AID-TOX3>3.0.CO;2-O](https://doi.org/10.1002/(SICI)1522-7278(1999)14:4<391::AID-TOX3>3.0.CO;2-O).
- 644 (40) Weldon, M.; VanEgdom, M. J.; Hendricks, K. A.; Regner, G.; Bell, B. P.; Sehulster, L. M.
645 Prevalence of Antibody to Hepatitis A Virus in Drinking Water Workers and Wastewater
646 Workers in Texas From 1996 to 1997. *J. Occup. Environ. Med.* **2000**, 42 (8), 821.
- 647 (41) Morace, G.; Aulicino, F. A.; Angelozzi, C.; Costanzo, L.; Donadio, F.; Rapicetta, M.
648 Microbial Quality of Wastewater: Detection of Hepatitis A Virus by Reverse Transcriptase-
649 polymerase Chain Reaction. *J. Appl. Microbiol.* **2002**, 92 (5), 828–836.
650 <https://doi.org/10.1046/j.1365-2672.2002.01587.x>.
- 651 (42) Arvanitidou, M.; Mamassi, P.; Vayona, A. Epidemiological Evidence for Vaccinating
652 Wastewater Treatment Plant Workers against Hepatitis A and Hepatitis B Virus. *Eur. J.*
653 *Epidemiol.* **2004**, 19 (3), 259–262. <https://doi.org/10.1023/B:EJEP.0000020444.64546.3b>.
- 654 (43) McCall, C.; Wu, H.; O'Brien, E.; Xagorarakis, I. Assessment of Enteric Viruses during a
655 Hepatitis Outbreak in Detroit MI Using Wastewater Surveillance and Metagenomic
656 Analysis. *J. Appl. Microbiol.* **2021**, 131 (3), 1539–1554. <https://doi.org/10.1111/jam.15027>.

- 657 (44) Prado, T.; Fumian, T. M.; Miagostovich, M. P.; Gaspar, A. M. C. Monitoring the Hepatitis A
658 Virus in Urban Wastewater from Rio de Janeiro, Brazil. *Trans. R. Soc. Trop. Med. Hyg.*
659 **2012**, *106* (2), 104–109. <https://doi.org/10.1016/j.trstmh.2011.10.005>.
- 660 (45) Hellmér, M.; Paxéus, N.; Magnius, L.; Enache, L.; Arnholm, B.; Johansson, A.; Bergström,
661 T.; Norder, H. Detection of Pathogenic Viruses in Sewage Provided Early Warnings of
662 Hepatitis A Virus and Norovirus Outbreaks. *Appl. Environ. Microbiol.* **2014**, *80* (21), 6771–
663 6781. <https://doi.org/10.1128/AEM.01981-14>.
- 664 (46) Yin, Z.; Voice, T. C.; Tarabara, V. V.; Xagorarakis, I. Sorption of Human Adenovirus to
665 Wastewater Solids. *J. Environ. Eng.* **2018**, *144* (11), 06018008.
666 [https://doi.org/10.1061/\(ASCE\)EE.1943-7870.0001463](https://doi.org/10.1061/(ASCE)EE.1943-7870.0001463).
- 667 (47) Hundekar, S.; Thorat, N.; Gurav, Y.; Lole, K. Viral Excretion and Antibody Titers in Children
668 Infected with Hepatitis A Virus from an Orphanage in Western India. *J. Clin. Virol.* **2015**,
669 *73*, 27–31. <https://doi.org/10.1016/j.jcv.2015.10.012>.
- 670 (48) Coulepis, A. G.; Locarnini, S. A.; Lehmann, N. I.; Gust, I. D. Detection of Hepatitis A Virus
671 in the Feces of Patients with Naturally Acquired Infections. *J. Infect. Dis.* **1980**, *141* (2),
672 151–156. <https://doi.org/10.1093/infdis/141.2.151>.
- 673 (49) Vestergaard, H. T.; Harritshøj, L. H.; Midgley, S. E.; Ullum, H.; Kampmann, P. Transfusion
674 Transmission of Hepatitis A Virus with Fecal Shedding in a Previously Hepatitis A
675 Vaccinated Recipient. *J. Infect. Chemother.* **2018**, *24* (9), 766–768.
676 <https://doi.org/10.1016/j.jiac.2018.01.020>.
- 677 (50) Nelson, N. P. Prevention of Hepatitis A Virus Infection in the United States:
678 Recommendations of the Advisory Committee on Immunization Practices, 2020. *MMWR*
679 *Recomm. Rep.* **2020**, *69*. <https://doi.org/10.15585/mmwr.rr6905a1>.